Abstract
Herpes simplex type-1 virus (HSV-1) based vectors have been widely used in different gene therapy approaches and also as experimental vaccines against HSV-1 infection. Recent advances in the HSV-1 technology do support the use of replication defective HSV-1 as vaccine vectors for delivery of foreign antigens. We have examined the ability of a recombinant replication-defective HSV-1 vector expressing the HIV-1 Tat protein to induce long-term Tat-specific immune responses in the Balb/c murine model. The results showed that vector administration by the subcutaneous route elicits anti-Tat specific T-cell mediated immune responses in mice characterized by the presence of the Tat-specific cytotoxic activity and production of high levels of IFN-gamma.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
AIDS Vaccines / administration & dosage
-
AIDS Vaccines / immunology*
-
Administration, Intranasal
-
Animals
-
Blotting, Western
-
Cell Proliferation
-
Chlorocebus aethiops
-
Enzyme-Linked Immunosorbent Assay
-
Gene Products, tat / biosynthesis*
-
Gene Products, tat / immunology*
-
Genetic Vectors
-
Herpesvirus 1, Human / genetics*
-
Herpesvirus 1, Human / immunology*
-
Immunization Schedule
-
Immunoglobulin G / biosynthesis
-
Immunoglobulin G / genetics
-
Injections, Subcutaneous
-
Interferon-gamma / immunology
-
Mice
-
Mice, Inbred BALB C
-
Plasmids / genetics
-
Spleen / cytology
-
Spleen / immunology
-
T-Lymphocytes / immunology*
-
Vaccines, Synthetic / immunology
-
Vero Cells
-
Virus Replication / genetics*
Substances
-
AIDS Vaccines
-
Gene Products, tat
-
Immunoglobulin G
-
Vaccines, Synthetic
-
Interferon-gamma